The progress of early cancer diagnoses in clinical laboratories

X.SongxiaoX.Songxiao
BulletArticle
RED 2024 Operational Excellence
Share this:
Copy link

Early diagnosis of cancer is critically important for the ideal prognosis of cancer patients. cfDNA-based new technologies have the potential to be the methodology for liquid biopsy of early cancer patients. Dr Xu Songxiao of Zhejiang Cancer Hospital discusses the progress of cfDNA methylation, fragmentome and microbiome studies, as well as the combined application of current biomarkers in this talk at RED 2024.

 

Share this:
Copy link

More on same topic

How diagnostics innovation empowers high-quality development in hospitals

Dr Gurpreet Singh on digital twins in healthcare and its impacts to patient monitoring at large

Recommended topics

SequencingRED 2020Rare Diseases
Next Read
  • C-Suite Perspectives, Event Coverage, Healthcare Transformation, Management, RED 2024
Dr William Morice II’s visions and considerations for building a global diagnostics ecosystem
How Awanui Group drives diagnostic excellence in New Zealand: Q&A with Anoop Singh (Part 1)
  • C-Suite Perspectives, Leaders In Conversation, Management
Awanui Group’s quest to improve lab diagnostics in New Zealand: Q&A with Anoop Singh (Part 1)
‘Real world evidence’ and clinical labs: a brief introduction
  • Healthcare Transformation, Management, Operations, Population Health Management
‘Real world evidence’ and clinical labs: a brief introduction
‘Chasing the Invisible’ and the future of the clinical lab: Q&A with Dr Thomas Grogan (Part 3)
  • Disease Area, Healthcare Transformation, Histopathology, Leaders In Conversation, Management, Oncology, Operations
‘Chasing the Invisible’ and the future of the clinical lab: Q&A with Dr Thomas Grogan (Part 3)
Scroll to Top